Combined Prognostic Value of Cardiac Magnetic Resonance–Derived Myocardial Extracellular Volume and the Fibrosis‐4 Index in Patients With Heart Failure With Preserved Ejection Fraction
- 3 November 2026
- journal article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (21) , e053485
Abstract
Background: Heart failure with preserved ejection fraction is increasingly recognized as a multisystem metabolic–inflammatory syndrome. We investigated the comparative and complementary prognostic value of cardiac magnetic resonance–derived extracellular volume fraction (ECV) and the Fibrosis‐4 index for predicting adverse cardiovascular outcomes in patients with heart failure with preserved ejection fraction. Methods: Between 2017 and 2019, 250 patients with heart failure with preserved ejection fraction underwent assessment of myocardial ECV by cardiac magnetic resonance and hepatic fibrosis using the Fibrosis‐4 index. The primary outcome was a composite of cardiovascular death or heart failure hospitalization. Multivariable Cox regression and discrimination analyses were performed to evaluate prognostic performance. Results: During a median follow‐up of 1190 days, 75 patients (30.0%) experienced the primary outcome. Both ECV (hazard ratio [HR], 1.13 [95% CI, 1.08–1.17]; P P =0.015) independently predicted the primary outcome. Patients with concomitantly elevated ECV and Fibrosis‐4 index had a markedly increased risk of adverse events compared with those with low values of both markers. ECV‐based models demonstrated superior discrimination compared with Fibrosis‐4–based models (concordance index, 0.732 versus 0.663; P =0.011). Addition of ECV to the Fibrosis‐4 model significantly improved discrimination, whereas addition of the Fibrosis‐4 index to the ECV model improved reclassification (continuous net reclassification improvement and integrated discrimination improvement) but not discrimination. Conclusions: Both myocardial ECV and the Fibrosis‐4 index independently predict adverse cardiovascular outcomes in heart failure with preserved ejection fraction. Although ECV provides greater prognostic discrimination, combined assessment of ECV and the Fibrosis‐4 index identifies a subgroup at particularly high risk and may provide complementary information for risk stratification.Keywords
This publication has 35 references indexed in Scilit:
- Metabolic Dysfunction-Associated Steatotic Liver Disease is Associated with Increased Risks of Heart FailureEuropean Journal of Heart Failure, 2025
- Single-cell transcriptomics reveal distinctive patterns of fibroblast activation in heart failure with preserved ejection fractionBasic Research in Cardiology, 2024
- Liver fibrosis according to diabetes status and relation to cardiovascular risk and mortality in US adultsAmerican Heart Journal Plus: Cardiology Research and Practice, 2024
- Synergistic effects of liver fibrosis and sarcopenia on endothelial dysfunction and arterial stiffness in patients with type 2 diabetesIJC Heart & Vasculature, 2022
- Fibrosis-4 Index Reflects Right Ventricular Function and Prognosis in Heart Failure with Preserved Ejection FractionESC Heart Failure, 2021
- Association of Liver Fibrosis Risk Scores with Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Findings from TOPCATESC Heart Failure, 2021
- Non-Alcoholic Fatty Liver Disease and Heart Failure with Preserved Ejection Fraction: From Pathophysiology to Practical IssuesESC Heart Failure, 2021
- Myocardial Adipose Deposition and the Development of Heart Failure with Preserved Ejection FractionEuropean Journal of Heart Failure, 2019
- Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection FractionJAMA Cardiology, 2017
- Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyondStatistics in Medicine, 2007